(ATNM) Actinium Pharmaceuticals, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ATNM) Actinium Pharmaceuticals, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This Actinium Pharmaceuticals, Inc. 4P's Marketing Mix Analysis outlines the company’s product offerings, pricing approach, distribution channels, and promotional tactics to show how it competes in oncology and radiopharmaceuticals; the page contains a genuine preview/sample of the report so you can evaluate style and content before buying — purchase the full version for the complete ready-to-use analysis.
Product
Iomab-B Phase III
Iomab-B (I-131 apamistamab) is Actinium Pharmaceuticals, Inc.'s lead and most advanced program, in a Phase III trial for conditioning older patients with relapsed or refractory acute myeloid leukemia before bone marrow transplant. The study targets a hard-to-treat group where transplant access can be limited. Actinium Pharmaceuticals, Inc. is using this asset as the core of its product strategy.
Iomab-B Phase I CAR T
Iomab-B is being tested in a Phase I study with CD19-targeted CAR T-cell therapy at Memorial Sloan Kettering Cancer Center, extending it into cellular therapy conditioning. The trial is small by design, but it matters because conditioning can shape CAR T expansion, safety, and response. For Actinium Pharmaceuticals, Inc., this adds a new clinical use case beyond transplant prep and broadens the product’s market reach.
Actinium-225 platform
Actinium Pharmaceuticals, Inc.’s Actinium-225 platform spans 3 isotopes: Actinium-225, Iodine-131, and Lutetium-177. It supports targeted radiotherapy and theranostic work, where one agent helps both image and treat tumors. The focus is precision oncology, aiming to deliver radiation more directly to cancer cells while limiting off-target damage.
Validated cancer markers
Actinium Pharmaceuticals, Inc. uses validated cancer markers across six targets: CD45, CD33, CD38, CD47, HER2, and HER3. These markers span hematologic cancers and solid tumors, giving the Company several shots on goal across the pipeline.
That target mix supports multiple product candidates and broadens the commercial base beyond one disease area.
- Six validated targets
- Blood and solid tumors
- Supports pipeline breadth
BMT and solid tumor uses
Actinium Pharmaceuticals, Inc. positions BMT and solid tumor uses around conditioning regimens for bone marrow transplant and cell therapy, plus standalone and combo cancer drugs. That mix gives it near-term transplant demand and longer-range oncology reach.
The BMT side targets the pre-treatment step that clears space for new cells, while solid tumor work widens the addressable market beyond transplant centers. In practice, that means one platform can serve both niche procedural use and larger cancer settings.
- Near-term use: transplant conditioning
- Broader use: solid tumors and combos
- Dual path: cell therapy plus oncology
Actinium’s Iomab-B Advances Toward a Potential AML Breakthrough
Actinium Pharmaceuticals, Inc. centers its Product strategy on Iomab-B (I-131 apamistamab), a Phase III conditioning drug for older patients with relapsed/refractory AML before transplant. It is also being tested in a Phase I MSK study with CD19 CAR-T, adding a second clinical use. The broader platform spans 3 isotopes and 6 validated targets.
| Metric | Data |
|---|---|
| Lead product | Iomab-B |
| Clinical stage | Phase III |
| Extra use case | Phase I with CD19 CAR-T |
| Platform breadth | 3 isotopes, 6 targets |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific 4P’s analysis of Actinium Pharmaceuticals, Inc.’s Product, Price, Place, and Promotion strategy.
Editable Excel File
Condenses Actinium Pharmaceuticals’ 4Ps into a quick, actionable snapshot for faster strategic review and alignment.
Reference Sources
Lists authoritative clinical, FDA, financial, and peer‑reviewed sources to speed verification and strengthen investment due diligence.
Place
New York, New York
Actinium Pharmaceuticals, Inc. is headquartered in New York, New York, and that base anchors its corporate, scientific, and investor activity. New York City, with about 8.3 million residents and a dense life sciences and capital markets hub, gives the Company direct access to talent, partners, and funding. For a biotech firm, this location supports fast communication with researchers, regulators, and investors.
Memorial Sloan Kettering
Memorial Sloan Kettering Cancer Center gives Actinium Pharmaceuticals access to one of the top U.S. oncology sites, which helps Iomab-B get tested in a high-expertise setting. The Phase 3 SIERRA study enrolled 153 patients, and MSK’s role supports clinical credibility, referral reach, and hard-to-replicate trial execution. That matters because centers like MSK can speed enrollment and sharpen data quality in complex blood cancer studies.
Astellas alliance
Actinium Pharmaceuticals, Inc. has a strategic collaboration with Astellas Pharma, Inc. focused on theranostics for solid tumors. That alliance gives Actinium access to Astellas’s global oncology reach, helping push its science beyond its U.S. home base. In the 4P mix, this place channel improves market access, credibility, and future launch reach.
EpicentRx alliance
Actinium Pharmaceuticals, Inc. works with EpicentRx, Inc. on a CD47 immunotherapy program that pairs targeted radiotherapy delivery with immune attack. That puts Actinium in a partnered biotech network, which can reduce solo R&D risk but also shares control of the asset. CD47 is a high-value cancer target because it helps tumors avoid immune clearance.
- Partnered CD47 program
- Targeted radiotherapy delivery
- Shared development risk
- Biotech network exposure
AVEO Oncology alliance
Actinium Pharmaceuticals, Inc. and AVEO Oncology are working on a HER3-targeting Antibody-Radio Conjugate for solid tumors, which widens clinical reach and future access through one more development site. In 2025, Actinium reported no product revenue and continued to fund pipeline work, so partner sites like AVEO matter for scale and trial flow.
- One more site for development
- Focus: HER3 solid tumors
- Supports future access
Actinium’s New York base powers its lean oncology reach
Actinium Pharmaceuticals, Inc. keeps place lean: headquarters in New York, plus trial and partner access through top oncology centers and alliances. In 2025, it reported no product revenue, so location, sites, and partners were key to reach and execution. New York also helps link science, capital, and regulators fast.
| Place factor | Data |
|---|---|
| HQ | New York, New York |
| 2025 revenue | 0 |
| Key access | MSK, Astellas, EpicentRx, AVEO |
Get Your Copy
Actinium Pharmaceuticals, Inc. Reference Sources
The preview shown here is the actual Actinium Pharmaceuticals, Inc. 4P's Marketing Mix analysis you’ll receive instantly after purchase—no surprises; it’s the full, final document, ready to download and use immediately.
Promotion
Phase III milestone
Phase III SIERRA data for Iomab-B is a strong promotion point for Actinium Pharmaceuticals, Inc. In the trial, 22% of patients achieved durable complete remission versus 0% in the control arm, giving clinicians and investors clear late-stage proof. That kind of data raises visibility with partners and supports the move toward potential commercialization.
Phase I CAR T update
Actinium Pharmaceuticals, Inc.’s Phase I CD19 CAR T update adds a second cell-therapy story beyond its core radiopharmaceutical work. Early-stage combination data can draw scientific interest and conference attention, especially in a field where CD19 remains the most validated CAR T target. Phase I results are still early, but they can help build credibility for expansion into cell therapy enabling.
Partnership announcements
Partnership announcements are a core promotion for Actinium Pharmaceuticals, Inc.: the company has highlighted 4 named collaborations with Astellas, EpicentRx, AVEO, and Memorial Sloan Kettering to validate its platform and widen scientific reach. These ties add external credibility and help position Actinium in broader oncology and radiopharma discussions, not just in-house R&D.
Targeted isotope platform
Actinium Pharmaceuticals, Inc.'s targeted isotope platform centers on three isotopes: Actinium-225, Iodine-131, and Lutetium-177. That 3-isotope message clearly sets it apart as a radiopharmaceutical developer, and it is the core story in both investor and medical outreach.
- 3 isotopes: Ac-225, I-131, Lu-177
- Clear radiopharma positioning
Clinical and investor communication
Actinium Pharmaceuticals, Inc. promotes mainly through trial updates, corporate releases, and SEC filings, which keep both investors and the oncology community informed before launch. Its message centers on 2 lead clinical programs, Iomab-B and Actimab-A, so every data readout can move awareness and sentiment fast.
- Trial updates drive visibility
- SEC filings support investor trust
- 2 lead programs shape the story
Actinium’s Iomab-B Delivers 22% Durable Remission, Backed by 4 Partnerships
Actinium Pharmaceuticals, Inc. promotes Iomab-B with SIERRA Phase III data: 22% durable complete remission versus 0% in control. That is its clearest late-stage proof point. The company also uses 4 named collaborations and 3 isotopes, Actinium-225, Iodine-131, and Lutetium-177, to widen reach and sharpen its radiopharma story.
| Promotion driver | Latest fact |
|---|---|
| Iomab-B SIERRA | 22% vs 0% |
| Collaborations | 4 named partners |
| Isotopes | 3 core isotopes |
Price
No approved product price
Actinium Pharmaceuticals, Inc. has no approved commercial product, so there is no official market list price for Iomab-B or any pipeline asset. Pricing is still unset because revenue generation depends on future regulatory approval. Until a product reaches market, the Price element of the mix stays theoretical, not commercial.
Clinical-stage valuation
Actinium Pharmaceuticals, Inc. is still in clinical development, so price is driven mainly by pipeline value, cash runway, and trial results, not product sales. Revenue-based drug pricing has not begun yet, because the business is not commercialized. In this phase, market value can move sharply on trial data and FDA milestones.
Future specialty pricing
If approved, Actinium Pharmaceuticals, Inc. would likely price its drugs as specialty oncology and radiopharmaceutical therapies, in line with peers like Novartis’ Pluvicto, which generated about $1.4 billion in 2024 sales. Hospital administration, complex isotope manufacturing, and supply limits would push prices higher than routine drugs. Reimbursement from Medicare and commercial payers would be decisive, since coverage often sets real net price.
Transplant-enabling economics
Iomab-B is built for bone marrow transplant conditioning, so Actinium Pharmaceuticals, Inc. can price it around a high-value, hospital-based procedure rather than a simple drug dose. That puts its economics closer to intensive-care oncology, where transplant episodes can cost well into the six figures and reimbursement is tied to outcomes, bed use, and supportive care intensity.
- Hospital procedure-linked pricing
- Targets transplant-conditioning value
- Fits ICU-level oncology economics
Combination therapy economics
Actinium Pharmaceuticals, Inc. is building several programs for use with CAR T and other cancer treatments, so combination pricing can support a premium if trials show clear added benefit. The main pricing driver is not the drug class alone, but proof of better response, lower relapse, or easier dosing versus standalone care.
Final price will depend on approval status, payer coverage, and access terms, especially in hospital-based oncology. If the combination improves outcomes enough to offset CAR T costs, which can exceed 400,000 dollars per patient in the US, payers may accept higher net pricing.
- Premium price needs clinical proof
- CAR T benchmarks are very high
- Payer access will set net price
Actinium’s Price Hinges on Iomab-B Approval and Payer Coverage
Actinium Pharmaceuticals, Inc. has no approved product, so Price is not set yet. If Iomab-B is approved, pricing would likely follow specialty oncology and transplant-conditioning economics, where access and reimbursement matter more than list price. Net price should hinge on FDA approval, payer coverage, and clinical proof of benefit.
| Price factor | Current status |
|---|---|
| Commercial price | No approved product |
| Pricing basis | Future specialty oncology |
| Net price driver | Payer coverage |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.